PharmX Technologies (ASX:PHX) Scaled Net Operating Assets: 0.70 (As of Dec. 2025)


ASX:PHX PharmX Technologies Ltd ASX:PHX
40 GF Score
Price A$0.13
GF Value A$0.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is PharmX Technologies Scaled Net Operating Assets?

PharmX Technologies ASX:PHX 40 Scaled Net Operating Assets is 0.70 as of Dec. 2025. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PharmX Technologies's operating assets for the quarter that ended in Dec. 2025 was A$14.79 Mil. PharmX Technologies's operating liabilities for the quarter that ended in Dec. 2025 was A$1.68 Mil. PharmX Technologies's Total Assets for the quarter that ended in Jun. 2025 was A$18.83 Mil. Therefore, PharmX Technologies's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2025 was 0.70.

PharmX Technologies Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for PharmX Technologies's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmX Technologies Scaled Net Operating Assets Chart

PharmX Technologies Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.57 0.31 0.08 0.42

PharmX Technologies Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.10 0.40 0.70 0.70

ASX:PHX vs VEEV, BTSG, TEM: Scaled Net Operating Assets Comparison

For the Health Information Services subindustry, PharmX Technologies's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmX Technologies Scaled Net Operating Assets vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where PharmX Technologies's Scaled Net Operating Assets falls into.


ASX:PHX
40GF Score
PharmX Technologies Ltd ASX:PHX
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmX Technologies Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

PharmX Technologies's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Jun. 2025 )
=(Operating Assets (A: Jun. 2025 )-Operating Liabilities (A: Jun. 2025 ))/Total Assets (A: Jun. 2024 )
=(14.653-2.003)/29.857
=0.42

where

Operating Assets(A: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=18.825 - 4.172
=14.653

Operating Liabilities(A: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.897 - 0.54 - 0.354
=2.003

PharmX Technologies's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2025 )
=(Operating Assets (Q: Dec. 2025 )-Operating Liabilities (Q: Dec. 2025 ))/Total Assets (Q: Jun. 2025 )
=(14.792-1.681)/18.825
=0.70

where

Operating Assets(Q: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=18.006 - 3.214
=14.792

Operating Liabilities(Q: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.402 - 0.398 - 0.323
=1.681

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.70 mean?
PharmX Technologies (ASX:PHX) has a Scaled Net Operating Assets of 0.70 as of Dec. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PharmX Technologies and its competitors.
Is PharmX Technologies' Scaled Net Operating Assets too high?
PharmX Technologies' current Scaled Net Operating Assets is 0.70. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' Scaled Net Operating Assets compare to VEEV and BTSG?
PharmX Technologies' Scaled Net Operating Assets of 0.70 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Healthcare Providers & Services company?
A good Scaled Net Operating Assets depends on the Healthcare Providers & Services industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on PharmX Technologies and its competitors. PharmX Technologies's current Scaled Net Operating Assets is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.13 — trading 85.7% above its estimated fair value. The current Scaled Net Operating Assets is 0.70. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current Scaled Net Operating Assets is 0.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmX Technologies (ASX:PHX) Overvalued in 2026?

Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued. The current stock price of A$0.13 is trading 85.7% above its estimated GF Value™ of A$0.07. GuruFocus considers PharmX Technologies to be Significantly Overvalued.

Key valuation signals for ASX:PHX:

  • Scaled Net Operating Assets: 0.70
  • GF Value™: A$0.07 vs. price of A$0.13 (85.7% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PharmX Technologies Business Description

Address 17 Castlereagh Street, Suite 11.02, Level 11, Sydney, NSW, AUS, 2000
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score

Get the complete analysis for ASX:PHX

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.13
Price
A$0.07
GF Value